metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population 9
mML - NA - PDL1 positive 1
mML - 1st line (L1)
mML - L1 - all population 7
mML - L1 - BRAF mutant 2
mML - L1 - BRAF wild 3
mML - 2nd line (L2)
mML - L2 - all population 11
mML - L2 - BRAF mutant 1
mesothelioma (MS)

All treatments
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open